<DOC>
	<DOCNO>NCT00660010</DOCNO>
	<brief_summary>The purpose study determine Lupron ( leuprolide acetate ) safe effective treat child Central Precocious Puberty ( CPP ) , assess long term effect leuprolide acetate treatment therapy discontinue .</brief_summary>
	<brief_title>Study Lupron Depot In The Treatment Central Precocious Puberty</brief_title>
	<detailed_description>This study include Prestudy Period ; treatment period subject receive treatment every 4 week initiation puberty ( age 12 male age 11 female ) ; follow-up period subject observe every 6 month physical laboratory observation pubertal level , every 12 month 5 year ; lastly final follow-up questionnaire give subject least 18 year old . At treatment visit , efficacy assessment Tanner stag ( suppression breast development female genital development male ) , gonadotropin ( LH FSH ) , sex steroid ( estradiol female testosterone male ) , ratio bone age chronological age , adult height compare standard population predict mature height , age time regular menses female . This protocol also capture data final questionnaire female reproductive status adulthood include presence regular menses number pregnancy .</detailed_description>
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Clinical diagnosis isosexual central precocious puberty onset Tanner score Stage II breast pubic hair earlier age 8.0 year girls Stage II pubic hair genitalia earlier 9.0 year boys . Confirmation diagnosis pubertal response gonadotropinreleasing hormone ( GnRH ) stimulation test ( LH &gt; 10 U/L baseline ) . Chronological age le 9.0 year girls less 10.0 year boys time first dosing . Bone age advance least 1 year beyond chronological age entry study . The condition may idiopathic secondary another lesion . If secondary , therapy primary condition undertaken stabilize . No evidence abnormal pituitary , adrenal , thyroid gonadal function except premature secretion gonadotropin . Irradiation central nervous system . Prior therapy medroxyprogesterone acetate and/or GnRH analog ( include prior treatment daily subcutaneous depot formulation leuprolide acetate ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>CPP</keyword>
	<keyword>central precocious puberty</keyword>
	<keyword>pediatrics</keyword>
	<keyword>suppression LH</keyword>
	<keyword>Lupron</keyword>
	<keyword>leuprolide acetate</keyword>
	<keyword>depot formulation</keyword>
	<keyword>GnRHa</keyword>
	<keyword>GnRH agonist</keyword>
	<keyword>GNRH analog</keyword>
	<keyword>LH</keyword>
	<keyword>Tanner stag</keyword>
</DOC>